Olema Pharmaceuticals (OLMA) Holds Near $11.31 as Phase 3 Data Timeline Extends into 2027
Key Takeaways
- OLMA shares have been essentially flat over the trailing 30 days, trading near $11.31 in mid-August 2026 — a low single-digit move that supports an overview rather than a price-driven narrative.
- The pivotal Phase 3 OPERA-01 trial for palazestrant completed enrollment, with top-line data now expected in the first quarter of 2027, resetting the near-term catalyst timeline.
- Second-quarter results showed a wider net loss driven by higher clinical development spending, while cash and marketable securities stood at $461.1 million as of June 30, 2026.
- Olema presented initial Phase 1 data for OP-3136 and expanded its clinical footprint through a collaboration with Bayer.
- Analyst sentiment remains broadly constructive, with a "Moderate Buy" consensus, even as several firms trimmed price targets.
Where OLMA Stands in the Market Right Now
From what I see, Olema Pharmaceuticals (NASDAQ: OLMA) traded near $11.31 in mid-August 2026, with a market capitalization of roughly $990 million. The shares sit well below their 52-week high of $36.26 and above the 52-week low of $5.34, reflecting a stock that has swung sharply with clinical news flow over the past year. Over the trailing 30 days, the price has moved only a few percentage points, holding in a comparatively narrow range as investors digest an evolving catalyst calendar. A post-earnings gap lower in early August was followed by a partial recovery, leaving the stock broadly in line with its late-July levels. This muted short-term move places the focus on the company's late-stage oncology pipeline rather than on short-term price momentum. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Olema’s Pipeline Focus and Competitive Edge
Olema Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted therapies for women's cancers, with a primary emphasis on estrogen receptor-positive (ER+), HER2-negative breast cancer. Its lead candidate, palazestrant (OP-1250), is an orally available small molecule that acts as both a complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD). Palazestrant is being evaluated as a monotherapy in the pivotal Phase 3 OPERA-01 trial and in combination with ribociclib in the Phase 3 OPERA-02 trial, with additional Phase 1/2 combination studies underway.
The company's second clinical candidate, OP-3136, is an oral inhibitor of KAT6, an epigenetic target dysregulated in breast and other cancers. Investors follow OLMA for its differentiated approach to endocrine-driven cancers and its potential to address acquired resistance to existing endocrine therapies — a meaningful clinical and commercial opportunity in a competitive but high-demand oncology space.
Recent Events Reshaping the OLMA Story
Several verified events have shaped investor sentiment over the past 30 days. The most consequential was the August 11, 2026 disclosure that Olema completed enrollment in the pivotal Phase 3 OPERA-01 trial while pushing top-line data expectations into the first quarter of 2027. The extended timeline triggered a sharp single-day decline as the market repriced the timing of the company's most important binary catalyst.
That news followed second-quarter results reported on August 10, 2026, when Olema posted a net loss of $63.2 million, up from $43.8 million a year earlier, and reported an EPS loss of $0.61, missing the consensus estimate of a $0.55 loss. The higher spend reflected investment in late-stage development of palazestrant and advancement of OP-3136. The company ended the quarter with $461.1 million in cash, cash equivalents, and marketable securities.
On the scientific front, Olema presented initial Phase 1 clinical data for OP-3136 at the 2026 ASCO Annual Meeting. Earlier in the year, the company entered a clinical trial collaboration and supply agreement with Bayer to evaluate OP-3136 in combination with darolutamide (Nubeqa) in patients with metastatic castration-resistant prostate cancer. Olema's addition to multiple Russell growth indices in June 2026 also broadened its institutional visibility. Against this backdrop, several analysts maintained Buy or Overweight ratings while lowering price targets to reflect the revised data timeline. I reviewed some of the sector context with Tickeron’s AI Daily Buy/Sell Signals to gauge broader sentiment around similar names.
What to Watch for OLMA Through the Rest of 2026
Looking ahead, the dominant driver for OLMA remains the Phase 3 OPERA-01 readout now expected in the first quarter of 2027, which makes near-term catalysts more dependent on earlier-stage data. Investors will closely monitor continued progress in OPERA-02, the palazestrant and ribociclib combination study, as well as expanding Phase 1 data for OP-3136, including combination readouts stemming from the Bayer collaboration.
Cash management is another key consideration: with $461.1 million on hand as of mid-2026 and a meaningful clinical spend, funding runway and potential dilution remain central to the investment case. Regulatory designations, medical conference presentations, and broader biotech financing conditions will also influence sentiment. As analyst price targets remain well above the current share price but have been trimmed in response to the revised timeline, the stock's trajectory is likely to remain tied to clinical execution and data delivery rather than near-term earnings.
Using AI Tools to Track Biotech Names
In my own research process, I’ve turned to Tickeron’s Trending AI Robots page to review how top-performing automated strategies are navigating volatility in sectors like biotechnology. The selection highlights bots with varying timeframes and risk profiles, offering a practical lens on how different approaches might align with holdings such as OLMA.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
OLMA in downward trend: 10-day moving average broke below 50-day moving average on August 17, 2026
The 10-day moving average for OLMA crossed bearishly below the 50-day moving average on August 17, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
OLMA moved below its 50-day moving average on August 20, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OLMA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 04, 2026. You may want to consider a long position or call options on OLMA as a result. In of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for OLMA just turned positive on September 02, 2026. Looking at past instances where OLMA's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where OLMA advanced for three days, in of 269 cases, the price rose further within the following month. The odds of a continued upward trend are .
OLMA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.233) is normal, around the industry mean (20.490). P/E Ratio (0.000) is within average values for comparable stocks, (28.270). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.510). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (444.384).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. OLMA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OLMA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement